Kypson A P, Peppel K, Akhter S A, Lilly R E, Glower D D, Lefkowitz R J, Koch W J
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
J Thorac Cardiovasc Surg. 1998 Mar;115(3):623-30. doi: 10.1016/S0022-5223(98)70327-7.
The ability to transfer genes to adult myocardium may have therapeutic implications for cardiac transplantation. We investigated the feasibility of adenovirus-mediated transfer of marker genes LacZ and Luciferase, as well as the potentially therapeutic gene of the human beta2-adrenergic receptor in a rat heterotopic heart transplant model.
Donor hearts were flushed with 10(12) total viral particles of one of three transgenes. Hearts were harvested at various time points after transplantation. LacZ-treated hearts were assessed by histologic staining and Luciferase-treated hearts were assayed for specific luminescence activity. Hearts treated with beta2-adrenergic receptor underwent radioligand binding assays and immunohistochemistry with the use of an antibody specific for the human beta2-adrenergic receptor.
LacZ hearts revealed diffuse myocyte staining as opposed to none within controls at 5 days. Luciferase hearts demonstrated a mean activity of 970,000 +/- 220,000 arbitrary light units versus 500 +/- 200 for the controls (p = 0.001). Total beta2-adrenergic receptor densities (fmol/mg membrane protein) for hearts that received the beta2-adrenergic receptor transgene at 3, 5, 7, 10, and 14 days after infection were as follows: right ventricle, 488.5 +/- 126.8, 519.4 +/- 81.8,* 477.1 +/- 51.8,* 183.0 +/- 6.5,* and 82.7 +/- 19.1; left ventricle, 511.0 +/- 167.6, 1206.4 +/- 321.8,* 525.3 +/- 188.7, 183.5 +/- 18.6,* and 75.9 +/- 15.2 (*p < 0.05 vs control value of 75.6 +/- 6.4). Immunohistochemical analysis revealed diffuse staining of varying intensity within myocardial sarcolemmal membranes.
We conclude that global overexpression of different transgenes is possible during cardiac transplantation and, ultimately, adenovirus-mediated gene transfer may provide a unique opportunity for genetic manipulation of the donor organ, potentially enhancing its function.
将基因转移至成年心肌的能力可能对心脏移植具有治疗意义。我们在大鼠异位心脏移植模型中研究了腺病毒介导的标记基因LacZ和荧光素酶以及人类β2 - 肾上腺素能受体潜在治疗基因转移的可行性。
用三种转基因之一的10¹²个总病毒颗粒冲洗供体心脏。在移植后的不同时间点采集心脏。对经LacZ处理的心脏进行组织学染色评估,对经荧光素酶处理的心脏测定特异性发光活性。对经β2 - 肾上腺素能受体处理的心脏进行放射性配体结合测定,并使用针对人类β2 - 肾上腺素能受体的特异性抗体进行免疫组织化学分析。
LacZ处理的心脏在5天时显示弥漫性心肌细胞染色,而对照组无染色。荧光素酶处理的心脏平均活性为970,000±220,000任意光单位,而对照组为500±200(p = 0.001)。在感染后3、5、7、10和14天接受β2 - 肾上腺素能受体转基因的心脏的总β2 - 肾上腺素能受体密度(fmol/mg膜蛋白)如下:右心室,488.5±126.8、519.4±81.8*、477.1±51.8*、183.0±6.5和82.7±19.1;左心室,511.0±167.6、1206.4±321.8、525.3±188.7、183.5±18.6*和75.9±15.2(*p < 0.05,与对照组值75.6±6.4相比)。免疫组织化学分析显示心肌肌膜内有不同强度的弥漫性染色。
我们得出结论,在心脏移植期间不同转基因的整体过表达是可能的,最终,腺病毒介导的基因转移可能为供体器官的基因操作提供独特机会,潜在地增强其功能。